Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05897112
Other study ID # CMHAbbottabad22
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date November 1, 2022
Est. completion date April 30, 2023

Study information

Verified date May 2023
Source Combined Military Hospital Abbottabad
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A total of sixty patients presented to the outpatient dermatology department of Combined military hospital (CMH) Abbottabad with signs of molluscum contagiosum clinically diagnosed meeting inclusion criteria were enrolled. Sample size was calculated using WHO sample size calculator. They were divided into two groups i.e Group A and Group B using lottery method. Patients in Group A were subjected to cryotherapy (liquid nitrogen gas) whereas patients in Group B patients were subjected to 10% potassium hydroxide solution for 3 weeks and were followed up at 2nd, 4th, 8th and 12th week for observing the progress of therapy in both groups on each follow up visit and ascertaining the efficacy respectively.


Recruitment information / eligibility

Status Completed
Enrollment 60
Est. completion date April 30, 2023
Est. primary completion date April 30, 2023
Accepts healthy volunteers No
Gender All
Age group 4 Years to 12 Years
Eligibility Inclusion Criteria: - clinical diagnosis of molluscum contagiosum having 3-20 lesion - no history of treatment before - willingness to participate (given by parents) Exclusion Criteria: - Patients with facial lesions - known immunodeficiency - tendency for hypertrophic scarring - known hypersensitivity

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Group A received cryotherpay
Group A were subjected to weekly cryotherapy with a cotton stick dip ped in Liquid Nitrogen for 02 Freezes and Thaw Cycle of 07 seconds with each cycle 10 seconds apart for 3 weeks
Group B received 10% Potassium Hydroxide Solution
Group B applied 10% potassium hydroxide aqueous solution twice daily with the help of a cotton tip applicator until lesion showed signs of inflammation or clearance for 3 weeks

Locations

Country Name City State
Pakistan CMH Abbottabad Abbottabad Khyber Pakhtunkhwa

Sponsors (1)

Lead Sponsor Collaborator
Combined Military Hospital Abbottabad

Country where clinical trial is conducted

Pakistan, 

Outcome

Type Measure Description Time frame Safety issue
Primary Efficacy was assessed at 12th week by the clearance of lesion or not Final evaluation in terms of efficacy was done at the follow up visit in 12th week and the method was termed as effective (Yes) on achieving complete clearance of lesions confirmed on clinical & physical examination of the affected areas by a consultant dermatologist using dermoscopy showing complete resolution of lesions. However, if lesions were not completely cleared at the end of 12th week, the treatment method was labelled as ineffective (No). 12 weeks
See also
  Status Clinical Trial Phase
Completed NCT03017846 - Safety and Efficacy of Topical Cantharidin for the Treatment of Molluscum Contagiosum, Phase 2 Phase 2
Recruiting NCT05937672 - Cold Atmospheric Plasma Device Extension Study Phase 3
Completed NCT04535531 - A Phase 3 Molluscum Contagiosum Efficacy and Safety Study Phase 3
Completed NCT02902822 - Tele-dermatology of Skin Cancer in a Cohort of Local Health Authority Employees in the Province of Bergamo N/A
Withdrawn NCT05536882 - MC RCT - BPO vs Adapalene Phase 3
Completed NCT03377790 - Cantharidin Application in Molluscum Patients-1 Phase 3
Completed NCT01348386 - Efficacy and Tolerance of Potassium Hydroxide (10% and 15%) in Molluscum Contagiosum Phase 2/Phase 3
Completed NCT05634460 - Comparison of 5% Potassium Hydroxide With 10% Potassium Hydroxide Solution in Treatment of Molluscum Contagiosum Phase 1
Completed NCT03186378 - Evaluation of Systemic Exposure to VP-102 in Subjects With Molluscum Contagiosum. Phase 2
Completed NCT03927716 - A Phase 3 Randomized Parallel Group Study Comparing the Efficacy & Safety of SB206 & Vehicle Gel in the Treatment of MC (B-SIMPLE1) Phase 3
Recruiting NCT04476186 - The Effectiveness of Oral Acyclovir in the Treatment of Molluscum Contagiosum in Children N/A
Completed NCT03927703 - A Phase 3 Efficacy & Safety of SB206 & Vehicle Gel for the Treatment of MC Phase 3
Completed NCT02665260 - Safety and Efficacy Study of Topical Cantharidin for the Treatment of Molluscum Contagiosum Phase 2
Completed NCT03436615 - A Study to Evaluate the Safety and Efficacy of SB206 in Subjects With Molluscum Contagiosum Phase 2
Recruiting NCT02759900 - Using a Cold Atmospheric Plasma Device to Treat Skin Disorders N/A
Completed NCT05680181 - Study of a Cohort of Children With Molluscum Contagiosum (MC) Treated With a 5% Solution of Potassium Hydroxide (Molutrex®) Applied Locally to the Skin
Completed NCT03077750 - A Study of VBP-245 in Pediatric Patients With Molluscum Contagiosum Phase 2
Terminated NCT02024581 - A Trial of a Botanical Drug Containing East Indian Sandalwood Oil (EISO) for the Treatment of Molluscum Contagiosum Phase 2
Completed NCT03377803 - Cantharidin Application in Molluscum Patients Phase 3
Withdrawn NCT03336372 - Picato for the Treatment of Molluscum Contagiosum in Immunocompromised Patients Early Phase 1